Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common shares
Reuters2026/08/11 01:32- Spyre Therapeutics director Jeffrey W. Albers exercised stock options to buy 5,000 common shares at USD 10.39 on Aug. 7.
- Albers sold 5,000 shares at a weighted average USD 104.47 on Aug. 7, reducing his direct stake to zero shares.
- Sessions LLC, an entity tied to Albers, sold 18,000 shares at weighted average prices near USD 104.38–104.68 on Aug. 7.
- Sessions LLC reported 9,360 shares of common stock remaining after the sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Arch Biopartners FY26 Q3 net loss widens 99.11% to CAD 475,112
Responding to the “hate wave” against data centers, Trump: Americans who oppose will “eventually fall behind and become poor”
US President Trump has publicly endorsed the construction of data centers and warned that slowing down AI infrastructure development would allow other countries to surpass the US. However, due to electoral pressures, many within the Republican Party have turned against these projects, with legislators in multiple states halting related initiatives. So far, dozens of data center projects across the country have been suspended due to local opposition, involving investments of approximately $150 billions.
BJ’s Restaurants director Bradford Richmond acquires 753 common shares worth $47,637.25
Crypto prices
More
